Chiral-Beta Asymmetric carbyne catalytic transfer to streamline synthesis of chiral β-amino carbonyls
- Coordinator
- Fundacio Institut Catala D'investigacio Quimica, Spain
- Runs
- 1 January 2025 to 31 December 2026
- Status
- Running
- EU funding
- €181k
- Total cost
- —
- Partners
- 2 organisations in 2 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101154411
What the project is doing
In the project's own words, from its summary on CORDIS.
The chiral β-amino carbonyl is an important structural motif prevalent in natural products and therapeutic agents. Despite that many methodologies have been developed for their diastero- and enantioselective synthesis, most of these methods require multistep manipulations with pre-functionalized substrates that fail to introduce the β-amino carbonyl moiety at the late-stage of complex molecule synthesis. Chiral-Beta aims to develop an innovative technology to rapidly construct chiral β-amino carbonyl derivatives with feedstock and fine alkenes as well as with complex drug molecules/natural products based on a Rh-catalyzed asymmetric carbyne transfer platform.
A key strength of this conceptually new and multidisciplinary proposal is the introduction of a secondment phase in Novartis (Basel) to explore real-life applications. The ambitious action merges perfectly the expertise of the host in novel C-H and C–C bond functionalization strategies based on the catalytic generation of carbyne equivalents with the strong background of the applicant in metal-catalyzed asymmetric reactions, thus enhancing two-way transfer of knowledge between the ER and the host group.
This project will expose the fellow to a wide range of cutting-edge chemistry and biomedical sciences in an interdisciplinary and international environment (ICIQ, Novartis) and enable the fellow to become a leader for the next generation in the field of chemical synthesis and late-stage functionalization techniques.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio Institut Catala D'investigacio Quimica | Tarragona | Spain | Coordinator |
| Novartis Pharma AG | Basel | Switzerland | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI